i) a monoglyceride having a purity of at least 80%, the monoglyceride having the formula



wherein R is selected from H and an acyl group containing from 6 to 24 carbon atoms with the proviso that two of the R groups are H, and

ii) a fatty acid with 6 to 24 carbon atoms, the acyl group of the fatty acid being saturated or unsaturated,

i) and ii) being present in the adjuvant in a weight ratio of from 0.1/50 to 50/1 so that the combination of i) and ii) elicits an immune response when administered to an animal.

66(Amended). An adjuvant according to claim 65, wherein the vaccine contains an antigen component.

67(Amended). An adjuvant according to claim 65, wherein the i) is at least 90%.

68(Amended). An adjuvant according to claim 65, wherein the i) is at least 95%.

69(Amended). An adjuvant according to claim 65, wherein the acyl group of the monoglyceride i) contains from 8 to 20 carbon atoms.

70(Amended). An adjuvant according to claim 65, wherein the acyl group of the monoglyceride i) contains from 14 to 20 carbon atoms.

71(Amended). An adjuvant according to claim 65, wherein the acyl group of the fatty acid ii) contains from 8 to 20 carbon atoms.

71 concl- 72(Amended). An adjuvant according to claim 65, wherein the acyl group of the fatty acid ii) contains from 14 to 20 carbon atoms.

73(Amended). A vaccine composition comprising an adjuvant according to claim 65, and an immunogenic quantity of an antigen component.

74(Amended). A vaccine or antigen composition according to claim 73, wherein the antigen component is capable of causing the formation of an immune response in animals including humans and marine animals.

75(Amended). A vaccine composition according to claim 74, wherein the antigen component is selected from the group consisting of antigens from pathogenic and non-pathogenic bacteria, viruses, parasites and tumor cells.

77(Amended). A vaccine composition according to claim 76, containing, in 100 g of the final composition:

from 0.01 to 90 g of the antigen component
from 1 to 20 g of the monoglyceride i)
from 1 to 20 g of the fatty acid ii)
from 0.01 to 99 g of water
from 0.01 to 99 g of PBS or saline
and optionally one or more additional adjuvants or excipients.

78(Amended). A vaccine composition, according to claim 77, wherein the composition comprises additional pharmaceutical excipients selected from the group consisting of preservatives, osmotic pressure controlling agents, pH-controlling agents, organic solvents, enzyme inhibitors, water absorbing polymers, absorption promoters and anti-oxidative agents.

84(Amended). A vaccine composition according to claim 73, wherein the content of monoglyceride i) of the adjuvant is at least 90%.

85(Amended). A vaccine composition according to claim 73, wherein the content of monoglyceride i) of the adjuvant is at least 95%.

86(Amended). A vaccine composition according to claim 73, wherein the acyl group of the monoglyceride i) of the adjuvant contains from 8 to 20 carbon atoms.

87(Amended). A vaccine composition according to claim 73, wherein the acyl group of the monoglyceride i) of the adjuvant contains from 14 to 20 carbon atoms.

74

90(Amended). A method of enhancing an immune response in a human or animal to an antigen administered to said human or animal, the method comprising administering an immune response enhancing effective amount of an adjuvant according to claim 65 to the human or animal.